ARFGAP2 (ADP-ribosylation factor GTPase-activating protein 2) is a regulatory protein involved in intracellular membrane trafficking, particularly in the Golgi apparatus. As a member of the ARFGAP family, it accelerates the hydrolysis of GTP bound to ADP-ribosylation factors (ARFs), switching ARFs from their active (GTP-bound) to inactive (GDP-bound) states. This activity is critical for modulating vesicle formation, cargo sorting, and cytoskeletal dynamics during vesicular transport. ARFGAP2 interacts with coat proteins and lipid bilayers, playing a role in COPI (coat protein complex I)-mediated retrograde transport and maintaining Golgi structure.
ARFGAP2 antibodies are immunological tools designed to detect and quantify ARFGAP2 expression in research applications. These antibodies are widely used in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to study ARFGAP2’s subcellular localization, protein-protein interactions, and regulatory mechanisms. Studies employing ARFGAP2 antibodies have linked the protein to cellular processes like secretion, receptor recycling, and lipid metabolism. Dysregulation of ARFGAP2 has been implicated in pathologies including cancer metastasis and neurodegenerative disorders, where aberrant membrane trafficking contributes to disease progression. Available as monoclonal or polyclonal variants, these antibodies are typically raised in hosts like rabbits or mice, with validation in specific experimental models to ensure specificity. Their use continues to advance understanding of ARFGAP2’s role in both physiological and disease contexts.